Biogen | BIIB - Selling And Administration Expenses

Stock Price
192.95
Daily Change
1.58 0.83%
Monthly
9.62%
Yearly
53.63%
Q2 Forecast
189.07

Biogen reported $554.3M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
ALKERMES USD 264.59M 77.4M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Esperion Therapeutics USD 39.42M 456K Dec/2025
Gilead Sciences USD 1.45B 326M Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
Merck USD 2.67B 180M Mar/2026
Moderna USD 173M 135M Mar/2026
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.33B 419M Mar/2026
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026